Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presentations SHANGHAI, April 26, 2023 /PRNewswire/ — Dizal today announced that multiple clinical data of its two leading assets – sunvozertinib and golidocitinib have been selected for…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.